Ann: FirstFlow Burette market update , page-7

I believe MLA have UK Distribution.

With regard to the profit split, my experience with other stocks in the Biotech industry is that the Manufacturer and Distributor/Marketer typically gets the lions share of the spoils, while the licensor picks up trailing royalties.

And as per the recent The Wise Owl report:

"The Concord Hospital contract remains in place, but additional local uptake has been slower than expected. In the absence of a US licensing deal, we estimate at least 17 new domestic hospital contracts will be needed for Analytica to reach a self-funding position."

This to me suggests that the split does indeed favour MLA in line with how traditional Licensor/Licensee arrangements might operate.